Belite Bio (BLTE) CSO pre-planned sale of 1,000 ADS around $160

Rhea-AI Filing Summary

Belite Bio Chief Scientific Officer Nathan L. Mata reported open-market sales of company stock. On May 1, 2026, he sold a total of 1,000 American depositary shares (ADS), with each ADS representing one ordinary share of Belite Bio.

The sales were executed in multiple trades at prices ranging from about $153.8 to $160 per ADS and were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. The filing does not show any option exercises or derivative transactions alongside these sales.

Insider Trade Summary 10b5-1

Net Seller: 1,000 shares ($155,778)

Net Sell 8 txns

Insider MATA NATHAN L.

Role Chief Scientific Officer

Sold 1,000 shs ($156K)

Type	Security	Shares	Price	Value
Sale	American depositary share	52	$153.8942	$8K
Sale	American depositary share	288	$154.3797	$44K
Sale	American depositary share	346	$155.476	$54K
Sale	American depositary share	82	$156.2415	$13K
Sale	American depositary share	106	$157.4518	$17K
Sale	American depositary share	65	$158.348	$10K
Sale	American depositary share	38	$159.0784	$6K
Sale	American depositary share	23	$160.00	$4K

Holdings After Transaction: American depositary share — 4,614 shares (Direct, null)

Footnotes (1)

1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025. Represents the weighted average price of shares sold at prices that ranged from $153.8 to $153.98. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $154 to $154.86. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $155 to $155.98. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $156 to $156.97. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $157.15 to $157.9. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $158 to $158.93. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $159 to $159.47. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

Key Figures

ADS sold: 1,000 ADS Highest sale price: $160.00 per ADS Lowest price range: $153.8–$153.98 per ADS +3 more

6 metrics

ADS sold 1,000 ADS Total open-market sales on May 1, 2026

Highest sale price $160.00 per ADS One of the May 1, 2026 transactions

Lowest price range $153.8–$153.98 per ADS Weighted average range noted in footnote F3

Number of sale transactions 8 transactions Non-derivative open-market ADS sales on May 1, 2026

Trading plan adoption date December 10, 2025 Rule 10b5-1 plan governing these sales

Net share change 1,000 share decrease Net-sell direction from transaction summary

Key Terms

American depositary share, Rule 10b5-1 trading plan, weighted average price

3 terms

American depositary share financial

"Each American depositary share represents one ordinary share, par value US$0.0001 per share"

An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"Represents the weighted average price of shares sold at prices that ranged from $153.8 to $153.98"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MATA NATHAN L.

(Last) (First) (Middle)

7708 MARKER ROAD

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American depositary share(1)	05/01/2026		S(2)		52	D	$153.8942(3)	4,614	D
American depositary share(1)	05/01/2026		S(2)		288	D	$154.3797(4)	4,326	D
American depositary share(1)	05/01/2026		S(2)		346	D	$155.476(5)	3,980	D
American depositary share(1)	05/01/2026		S(2)		82	D	$156.2415(6)	3,898	D
American depositary share(1)	05/01/2026		S(2)		106	D	$157.4518(7)	3,792	D
American depositary share(1)	05/01/2026		S(2)		65	D	$158.348(8)	3,727	D
American depositary share(1)	05/01/2026		S(2)		38	D	$159.0784(9)	3,689	D
American depositary share(1)	05/01/2026		S(2)		23	D	$160	3,666	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025.

3. Represents the weighted average price of shares sold at prices that ranged from $153.8 to $153.98. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

4. Represents the weighted average price of shares sold at prices that ranged from $154 to $154.86. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

5. Represents the weighted average price of shares sold at prices that ranged from $155 to $155.98. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

6. Represents the weighted average price of shares sold at prices that ranged from $156 to $156.97. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

7. Represents the weighted average price of shares sold at prices that ranged from $157.15 to $157.9. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

8. Represents the weighted average price of shares sold at prices that ranged from $158 to $158.93. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

9. Represents the weighted average price of shares sold at prices that ranged from $159 to $159.47. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

	/s/ Nathan L. Mata	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Belite Bio (BLTE) report for Nathan L. Mata?

Belite Bio reported that Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares in open-market transactions on May 1, 2026. These trades were disclosed on a Form 4 and represent direct ownership transactions in Belite Bio’s ADSs.

At what prices did the Belite Bio (BLTE) CSO sell his 1,000 ADS?

Nathan L. Mata’s 1,000 ADS sales occurred in multiple trades at prices ranging from approximately $153.8 to $160 per ADS. Several trades used weighted average prices within narrower ranges, as detailed in the Form 4 footnotes for the reported transactions.

Was the Belite Bio (BLTE) insider sale done under a Rule 10b5-1 plan?

Yes. The Form 4 states that Nathan L. Mata’s sales were effected under a Rule 10b5-1 trading plan adopted on December 10, 2025. Such pre-arranged plans automate trades according to preset instructions, reducing the significance of short-term market timing.

How many separate sale transactions did the Belite Bio (BLTE) CSO execute?

The filing lists eight separate open-market sale transactions of American depositary shares on May 1, 2026. Together, these eight trades total 1,000 ADS sold, with each trade reported with its own share amount and weighted average sale price on the Form 4.

What security did the Belite Bio (BLTE) insider sell in this Form 4?

Nathan L. Mata sold Belite Bio American depositary shares, with each ADS representing one ordinary share of the company. All reported transactions involve non-derivative ADS holdings, and the filing does not show any related option exercises or derivative conversions.